Skip to main content

Table 6 Concordance indexes for resected pancreatic cancer in training and validation cohorts and in sensitivity analyses for the training US cohort

From: Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study

Model modification/subgroup Concordance index 95% confidence interval
Training cohort
 The US, our nomogram 0.60 0.59–0.61
 The US, model based on both T and N stages 0.56 0.56–0.57
Validation cohorts
 Belgium, our nomogram 0.58 0.55–0.60
 Belgium, model based on both T and N stages 0.54 0.52–0.56
 The Netherlands, our nomogram 0.62 0.59–0.65
 The Netherlands, model based on both T and N stages 0.56 0.54–0.59
 Slovenia, our nomogram 0.58 0.51–0.65
 Slovenia, model based on both T and N stages 0.52 0.47–0.57
 Norway, our nomogram 0.63 0.55–0.71
 Norway, model based on both T and N stages 0.61 0.54–0.68
Sensitivity analyses for the training US cohort
 Replacement
  Age group in place of continuous age 0.59 0.59–0.60
  Metastatic lymph node number in place of N stage 0.60 0.59–0.61
  Lymph node ratio in place of N stage 0.61 0.61–0.62
  The 8th version of T stage in place of the original stage 0.61 0.60–0.61
  The 8th version of N stage in place of the original stage 0.60 0.59–0.61
  The 8th version of T & N stages in place of the original stages 0.61 0.60–0.62
 Addition
  Harvested lymph node added 0.60 0.60–0.61
  Tumor size added 0.61 0.60–0.61
  Harvested lymph node & tumor size added 0.61 0.60–0.62
 Subgroup
  Diagnosis after 2009 0.60 0.59–0.61
  White ethnicity 0.60 0.59–0.61
  Pancreas head 0.60 0.59–0.61
  Pancreas body & tail 0.61 0.59–0.63
  1. Concordance indexes in sensitivity analyses greater than that for the overall nomogram in the US are highlighted in italics